Since receiving approval from the U.S. Food and Drug Administration in 2023 as only the second Alzheimer’s-modifying drug, sales of lecanemab, marketed as Leqembi, have consistently increased ...

Analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab (August 1, 2023, to October 1, 2024).

Lecanemab also binds to fibrils, which comprise amyloid plaques, but with a 10-fold greater affinity for protofibrils relative to fibrils (Soderberg et al., 2023). Fertan et al. describe the binding ...

Interim findings showed treatment with SC lecanemab resulted in 14% greater amyloid plaque removal in the brain at 6 months, assessed by amyloid positron emission tomography, compared with ...

Key takeaways: Lecanemab led to a 44% reduction of biomarker MTBR-tau243 at 18 months. MTBR-tau243 levels increase over time and track with changes in tau positron emission tomography.

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union ...